{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:06Z","timestamp":1793830446135,"version":"4.6.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"name":"the Science Foundation of Peking University Cancer Hospital","award":["BJCH2024CZ02"],"award-info":[{"award-number":["BJCH2024CZ02"]}]},{"name":"National Key Research and Development Program of China","award":["2022YFC2406901"],"award-info":[{"award-number":["2022YFC2406901"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82372001"],"award-info":[{"award-number":["82372001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82171980"],"award-info":[{"award-number":["82171980"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["92359203"],"award-info":[{"award-number":["92359203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82171973"],"award-info":[{"award-number":["82171973"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Clinical Medicine Excellent Talent Training Program of Hebei Province","award":["ZF2024223"],"award-info":[{"award-number":["ZF2024223"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To compare the performance of Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT in detecting bone metastases, with or without visceral metastases, in HER2-positive breast cancer patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This retrospective study included 64 participants with HER2-positive breast cancer who underwent both Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT. All participants had pathologically confirmed HER2-positive status, defined as either IHC 3+ or IHC 2+ with gene amplification on FISH. Two independent readers visually assessed uptake of tracers on imaging. Bone lesions were classified as osteolytic, osteoblastic, mixed-pattern, or CT-occult based on their radiographic characteristics. Lesion uptake was quantified using both maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR), with statistical comparison performed through general linear mixed modeling. Final diagnoses were established through histopathologic confirmation or clinical follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The findings showed bone metastases in 23 (35.9%) participants, including 2 (8.7%) had pure bone metastases, 21 (91.3%) concurrent visceral metastases. On a per-patient analysis, the sensitivity, specificity, and accuracy of Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH and\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG were 100.0%, 95.1%, 96.9%, and 87.0%, 97.6%, 93.8%, respectively. Three (13.0%) participants were visualized only on Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH, and 10 (43.5%) were detected more lesions on Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH than\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT. Regarding visceral metastases, Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH alone detected metastases in 4 participants (19.0%), identified more lesions than\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG in 5 participants (23.8%), and showed equal detection in 12 participants (57.1%). On a per-lesion analysis, PET\/CT identified 238 bone metastases, with Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH achieving complete detection (238\/238, 100%) compared with\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG\u2019s identification of only 143 lesions (143\/238, 60.1%). Notable detection differences emerged in: osteoblastic (100% vs. 0%), osteolytic (100% vs. 87.5%), and CT-occult lesions (100% vs. 50.6%) for Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH versus\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG, respectively. Quantitative comparison revealed Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH PET\/CT achieved 2.7\u20135.9 folds higher SUVmax and TBR values versus\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT across osteogenic, osteolytic, and CT-occult lesions (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). In addition, Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH detected more bone metastases small than 10\u00a0mm than\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT (183 vs. 95, 100.0% vs. 50.3%). No adverse reactions related to imaging agents were observed in all participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Compared with\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT, Al\n                      <jats:sup>18<\/jats:sup>\n                      F-NOTA-HER2-BCH PET\/CT demonstrated superior detection of bone metastases in HER2-positive breast cancer participants, particularly for early-stage CT-occult lesions and sub-centimeter (&lt;10\u00a0mm) metastases. In addition, it showed potential for earlier identification of concurrent visceral metastases.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006249","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T19:00:10Z","timestamp":1767207610000},"page":"123-131","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Al18F-NOTA-HER2-BCH Versus 18F-FDG PET\/CT for Detecting Bone Metastases"],"prefix":"10.1097","volume":"51","author":[{"given":"Xiaoyi","family":"Guo","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Ma","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-4146","authenticated-orcid":false,"given":"Xu","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, First Affiliated Hospital of Hebei North University, Zhangjiakou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Zhou","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"R1-20260107","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260107","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","article-title":"Invasion and metastasis in cancer: molecular insights and therapeutic targets","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"R3-20260107","doi-asserted-by":"crossref","first-page":"103416","DOI":"10.1016\/j.critrevonc.2021.103416","article-title":"Bone marrow\/bone pre-metastatic niche for breast cancer cells colonization: the role of mesenchymal stromal cells","volume":"164","author":"Sanmartin","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"R4-20260107","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"key":"R5-20260107","first-page":"004","article-title":"Metastatic bone disease: pathogenesis and therapeutic options: Up-date on bone metastasis management","volume":"15","author":"D\u2019Oronzo","year":"2019","journal-title":"J Bone Oncol"},{"key":"R6-20260107","doi-asserted-by":"crossref","first-page":"108280","DOI":"10.1016\/j.pharmthera.2022.108280","article-title":"Therapeutics targeting the metastatic breast cancer bone microenvironment","volume":"239","author":"Ihle","year":"2022","journal-title":"Pharmacol Ther"},{"key":"R7-20260107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"R8-20260107","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.trecan.2018.12.004","article-title":"Bone metastasis: find your niche and fit in","volume":"5","author":"Zhang","year":"2019","journal-title":"Trends Cancer"},{"key":"R9-20260107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","article-title":"The matrix in cancer","volume":"21","author":"Cox","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"R10-20260107","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/annonc\/mds169","article-title":"The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis","volume":"23","author":"Hadji","year":"2012","journal-title":"Ann Oncol"},{"key":"R11-20260107","doi-asserted-by":"crossref","first-page":"a031252","DOI":"10.1101\/cshperspect.a031252","article-title":"The biology of bone metastasis","volume":"8","author":"Esposito","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R12-20260107","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-23-0543","article-title":"Bone-induced HER2 promotes secondary metastasis in HR+\/HER2- breast cancer","volume":"15","author":"Alam","year":"2025","journal-title":"Cancer Discov"},{"key":"R13-20260107","doi-asserted-by":"crossref","first-page":"8714","DOI":"10.1007\/s00330-021-07956-0","article-title":"Prospective comparison of the diagnostic accuracy of 18F-FDG PET\/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients","volume":"31","author":"Bruckmann","year":"2021","journal-title":"Eur Radiol"},{"key":"R14-20260107","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.semnuclmed.2024.10.008","article-title":"Diagnosing bone metastases in breast cancer: a systematic review and network meta-analysis on diagnostic test accuracy studies of 2-[(18)F]FDG-PET\/CT, (18)F-NaF-PET\/CT, MRI, contrast-enhanced CT, and bone scintigraphy","volume":"55","author":"Gerke","year":"2025","journal-title":"Semin Nucl Med"},{"key":"R15-20260107","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.120.244640","article-title":"Assessment of bone lesions with (18)F-FDG PET compared with (99m)Tc bone scintigraphy leads to clinically relevant differences in metastatic breast cancer management","volume":"62","author":"van Es","year":"2021","journal-title":"J Nucl Med"},{"key":"R16-20260107","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S1470-2045(22)00642-8","article-title":"Intra-individual comparison of (18)F-sodium fluoride PET-CT and (99m)Tc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial","volume":"23","author":"B\u00e9nard","year":"2022","journal-title":"Lancet Oncol"},{"key":"R17-20260107","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.biopha.2012.06.004","article-title":"Early bone marrow metastasis detection: the additional value of FDG-PET\/CT vs. CT imaging","volume":"66","author":"Evangelista","year":"2012","journal-title":"Biomed Pharmacother"},{"key":"R18-20260107","doi-asserted-by":"crossref","first-page":"e232209","DOI":"10.1148\/radiol.232209","article-title":"Comparison of an affibody-based molecular probe and (18)F-FDG for detecting HER2-positive breast cancer at PET\/CT","volume":"311","author":"Guo","year":"2024","journal-title":"Radiology"},{"key":"R19-20260107","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1007\/s00259-025-07251-w","article-title":"Al(18)F-NOTA-HER2-BCH versus (18)F-FDG PET\/CT in evaluating newly diagnosed HER2-low breast cancer patients","volume":"52","author":"Guo","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-20260107","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1007\/s00259-023-06232-1","article-title":"Comparison of renal clearance of [(18)F]AlF-RESCA-HER2-BCH and [(18)F]AlF-NOTA-HER2-BCH in mice and breast cancer patients","volume":"50","author":"Liu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-20260107","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrc3838","article-title":"Translational biology of osteosarcoma","volume":"14","author":"Kansara","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"R22-20260107","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","article-title":"Latent bone metastasis in breast cancer tied to Src-dependent survival signals","volume":"16","author":"Zhang","year":"2009","journal-title":"Cancer Cell"},{"key":"R23-20260107","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"R24-20260107","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.suronc.2013.01.002","article-title":"Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis","volume":"22","author":"Rong","year":"2013","journal-title":"Surg Oncol"},{"key":"R25-20260107","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1186\/s12885-025-14187-9","article-title":"De Novo bone metastasis in breast cancer: tumor biology and survival outcomes in a retrospective study from Pakistan","volume":"25","author":"Anwar","year":"2025","journal-title":"BMC Cancer"},{"key":"R26-20260107","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/s41422-023-00810-6","article-title":"SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches","volume":"33","author":"Wu","year":"2023","journal-title":"Cell Res"},{"key":"R27-20260107","doi-asserted-by":"crossref","first-page":"54","DOI":"10.12998\/wjcc.v8.i1.54","article-title":"Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: a study of 1358 patients","volume":"8","author":"Cui","year":"2020","journal-title":"World J Clin Cases"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:55:16Z","timestamp":1786035316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006249"}},"subtitle":["Sensitivity and Quantitative Comparison"],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006249","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"2025-07-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}